Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KER-0193
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kaerus' KER-0193 Shows Proof of Mechanism in Phase 1 for Fragile X Syndrome
Details : KER-0193, a novel BK channel modulator, small molecule drug candidate, which is being evaluated for the treatment of Fragile X syndrome.
Product Name : KER-0193
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2025
Lead Product(s) : KER-0193
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KER-0193
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kaerus Bioscience Initiates Phase 1 Trial for KER-0193 in Fragile X Syndrome
Details : KER-0193 is a novel, proprietary, and orally-bioavailable small molecule modulator of BK channels, being developed for patients with Fragile X Syndrome.
Product Name : KER-0193
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2024
Lead Product(s) : KER-0193
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
